1-4 of 4
Gopichand Pendurti
Close
Sort by
Journal Articles

What Is the Patient Risk from a Bone Marrow Biopsy By Hematologists-in-Training? A Prospective, Clinical Study

Shirin Attarian, MD, Louis Juden Reed, MD, Shashi Singh, MD, Gopichand Pendurti, MBBS, Alexander Shestopalov, MD, Aditi P. Singh, MD, Anjali Budhathoki, MD, Simon Abi Aad, MD, Urvi A Shah, MD, Salem Kim, MD, Kimo Bachiashvili, MD, Tarek Elrafei, DO, Karenza Alexis, MD, Marianna Strakhan, MD, Weijuan Li, MS,MD, Conway Yee, MD, Ellen W. Friedman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5638.
https://doi.org/10.1182/blood.V130.Suppl_1.5638.5638
Published: 2017
Journal Articles

PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome

Ashley Pandolfi, Robert F. Stanley, Yiting Yu, Boris Bartholdy, Gopichand Pendurti, Kira Gritsman, Jacqueline Boultwood, Jonathan Chernoff, Amit Verma, Ulrich Steidl
Journal: Blood
Blood (2015) 126 (9): 1118–1127.
https://doi.org/10.1182/blood-2014-12-618801
Published: 2015
Includes: Supplemental data
Journal Articles

Ofatumumab (OFA) Is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity in Vitro and in Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models.

Matthew J. Barth, MD, Gopichand Pendurti, MD, Ping-Chiao Tsai, PhD, Cory Mavis, BSc, MSc, Pavel Klener, Jr., Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2012) 120 (21): 2757.
https://doi.org/10.1182/blood.V120.21.2757.2757
Published: 2012
Journal Articles

Blastoid Variant of Mantle Cell Lymphoma (MCL) Is Associated with P53 Abnormalities and Have a Shorter Progression-Free Survival (PFS) and Overall Survival (OS) Despite Upfront Chemo-Immunotherapy Followed by High Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS)

Lyudmyla Derby, MD, Gopichand Pendurti, MD, George Deeb, MD, Sheila Sait, PhD, Annmarie Block, PhD, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2010) 116 (21): 1773.
https://doi.org/10.1182/blood.V116.21.1773.1773
Published: 2010